Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: An update from the Group for the Respect of Ethics and Excellence in Science (Osteoporosis International DOI: 10.1007/s00198-008-0670-7);Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: An update from the Group for the Respect of Ethics and Excellence in Science

Osteoporosis International

Volumn 19, Issue 9, 2008, Pages 1247-1250

  Compston, J ^a   Reid, D M ^b   Boisdron, J ^c   Brandi, M L ^d   Burlet, N ^e   Cahall, D ^f   Delmas, P D ^g   Dere, W ^h   Devogelaer, J P ⁱ   Fitzpatrick, L A ^j   Flamion, B ^k   Goel, N ^l   Korte, S ^m   Laslop, A ⁿ   Mitlak, B ^o   Ormarsdottir, S ^p   Ringe, J ^q   Rizzoli, R ^r   Tsouderos, Y ^s   Van Staa, T ^t   Reginster, J Y ^u,v   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF FLORENCE   (Italy)

^e International Osteoporosis Foundation Switzerland   (Switzerland)

^f Sanofi Synthelabo Groupe   (United States)

^g UNIVERSITÉ DE LYON   (France)

^h AMGEN INC   (United States)

ⁱ UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^j GLAXOSMITHKLINE   (United States)

^k UNIVERSITY OF NAMUR   (Belgium)

^l UCB PHARMA   (Belgium)

^m Novartis Pharma AG   (Switzerland)

ⁿ AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^o ELI LILLY AND COMPANY   (United States)

^p Icelandic Medicines Control Agency   (Iceland)

^q KLINIKUM LEVERKUSEN   (Germany)

^r GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^s INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^t MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^u UNIVERSITY OF LIÈGE   (Belgium)

^v GREES   (Belgium)

more..

Author keywords

Bone mineral density; Bridging study; Glucocorticoid induced osteoporosis; Men; Phase III studies; Postmenopausal women

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; PLACEBO; PREDNISOLONE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FRACTURE; GERIATRIC CARE; HUMAN; MEDICAL ETHICS; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS; RESEARCH DESIGN; SEX FACTORS;

EID: 49549117542     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0735-7     Document Type: Erratum

References (21)

1. TP van Staa HGM Leufkens L Abenhaim B Begaud B Zhang C Cooper 2000 Use of oral corticosteroids in the United Kingdom Q Med J 93 105 111
2. E Canalis JP Bilezekian A Angeli A Giustina 2004 Perspectives on glucocorticoid-induced osteoporosis Bone 34 593 598
3. TP van Staa HGM Leufkens C Cooper 2002 A meta-analysis of the epidemiology of corticosteroid-induced osteoporosis Osteoporos Int 13 777 787
4. TP van staa HGM Leufkens L Abenhaim B Zhang C Cooper 2000 Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatol 39 1383 1389
5. T Van Staa HGM Leufkens L Abenhaim B Zhang C Cooper 2000 Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 993 1000
6. RFJM Laan PLCM Van Riel LBA van de Putte LJTO van Erning MA van't Hof JAM Lemmens 1993 Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid-arthritis - a randomized, controlled-study Ann Intern Med 119 963 968
7. JA Kanis H Johansson A Oden 2004 A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 893 899
8. M Luengo C Picado L Del Rio N Guanabens JM Montserrat J Setoain 1990 Treatment of steroid-induced osteopenia with calcitonin in corticosteroid- dependent asthma Am Rev Resp Dis 142 104 107
9. TP van Staa RF Laan IP Barton S Cohen DR Reid C Cooper 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 3224 3229
10. L Dalle Carbonare ME Arlot PM Chavassieux JP Roux NR Portero PJ Meunier 2001 Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis J Bone Miner Res 16 97 103
11. C Bresssot PJ Meunier MC Chapuy 1979 Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis Metab Bone Dis Rel Res 1 303 311
12. DW Dempster 1989 Bone histomorphometry in glucocorticoid-induced osteoporosis J Bone Miner Res 4 137 147
13. DW Dempster MA Arlot PJ Meunier 1983 Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis Calcif Tissue Int 35 410 417
14. JE Compston J-Y Reginster B Avouac 1996 Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis Calcif Tissue Int 59 323 327
15. EC Abadie J-P Devogelaer JD Ringe 2005 Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science Sem Arthritis Rheum 35 1 4
16. KG Saag R Emkey TJ Schnitzer 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis New Engl J Med 339 292 299
17. S Cohen RM Levy M Keller 1999 Risedronate therapy prevents corticosteroid-induced bone loss Arthritis Rheum 42 2309 2318
18. DM Reid RA Hughes RFJM Laan 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial J Bone Miner Res 15 1006 1013
19. ES Orwoll M Ettinger S Weiss 2000 Alendronate for the treatment of osteoporosis in men New Engl J Med 343 604 610
20. R Bobba JD Adachi 2007 Review of the safety and efficacy for the treatment of male osteoporosis Clin Interv Aging 2 275 282
21. ES Orwoll WH Scheele S Paul 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 9 17